The Evolution of Primary Multimodality Treatment in Resectable Breast Cancer

August 1980 in “ Cancer ”

Jane E. Henney, Vincent T. DeVita

chemotherapy estrogen receptor adjuvant therapy axillary lymph node involvement

Studysummary This study found that administering chemotherapy to premenopausal women with Stage II breast cancer significantly improved disease-free intervals and increased survival, while postmenopausal women receiving sufficient doses also saw prolonged disease-free periods.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer ·

View this study on onlinelibrary.wiley.com →

Discuss this study in the Community →

Similar Research

5 / 1000+ results

research Patient-Reported Outcomes From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer

1 citations , July 2021 in “Frontiers in Oncology”

This study found that patient-reported outcomes were similar between neoadjuvant endocrine therapy and chemotherapy in premenopausal breast cancer patients, but future perspective was significantly better with endocrine therapy.

Postoperative Chemotherapy and Tamoxifen Compared with Tamoxifen Alone in the Treatment of Positive-Node Breast Cancer Patients Aged 50 Years and Older with Tumors Responsive to Tamoxifen: Results from the National Surgical Adjuvant Breast and Bowel Project B-16

research Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16.

279 citations , June 1990 in “Journal of Clinical Oncology”

The study found that for positive-node breast cancer patients aged 50 and older, adding chemotherapy to tamoxifen significantly improved disease-free survival compared to tamoxifen alone.

research Feasibility and tolerability of eribulin-based chemotherapy versus other chemotherapy regimens for patients with metastatic triple-negative breast cancer: a single-centre retrospective study

February 2024 in “Frontiers in Cell and Developmental Biology”

This study found that eribulin-based chemotherapy resulted in longer median progression-free and overall survival, with fewer side effects, for advanced triple-negative breast cancer patients compared to other chemotherapy options.

research Prolonged remissions of metastatic breast cancer achieved with a six-drug regimen of relatively low toxicity

6 citations , June 1983 in “Cancer”

This study found that a chemotherapy regimen combining CMFVP and ACP treatments for unresectable metastatic breast cancer yielded a 66.7% overall response rate, with premenopausal women responding more favorably than postmenopausal women.

research The Safety of Local Hormonal Treatment for Vulvovaginal Atrophy in Women With Estrogen Receptor-positive Breast Cancer Who Are on Adjuvant Aromatase Inhibitor Therapy: Meta-analysis

18 citations , August 2019 in “Clinical breast cancer”

This meta-analysis found that in postmenopausal women with a history of breast cancer, 8 weeks of vaginal estrogen therapy while on aromatase inhibitors did not result in systemic absorption of sex hormones, suggesting potential safety for treating vulvovaginal atrophy in this context.